Last Updated: November 16, 2026

ZONGERTINIB - Generic Drug Details

« Back to Dashboard


What are the generic drug sources for zongertinib and what is the scope of freedom to operate?

Zongertinib is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ZONGERTINIB
International Patents:106
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 8
Patent Applications: 14
What excipients (inactive ingredients) are in ZONGERTINIB?ZONGERTINIB excipients list
DailyMed Link:ZONGERTINIB at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZONGERTINIB
Generic Entry Date for ZONGERTINIB*:
Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZONGERTINIB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boehringer IngelheimPHASE3
Boehringer IngelheimPHASE2
Boehringer IngelheimPHASE1

See all ZONGERTINIB clinical trials

Pharmacology for ZONGERTINIB

US Patents and Regulatory Information for ZONGERTINIB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim HERNEXEOS zongertinib TABLET;ORAL 219042-001 Aug 8, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Boehringer Ingelheim HERNEXEOS zongertinib TABLET;ORAL 219042-001 Aug 8, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Boehringer Ingelheim HERNEXEOS zongertinib TABLET;ORAL 219042-001 Aug 8, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ZONGERTINIB

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1971601 21C1031 France ⤷  Start Trial PRODUCT NAME: TUCATINIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/20/1526 20210212
1971601 C20210018 00331 Estonia ⤷  Start Trial PRODUCT NAME: TUKATINIIB;REG NO/DATE: EU/1/20/1526 12.02.2021
1971601 SPC/GB21/042 United Kingdom ⤷  Start Trial PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU/1/20/1526(FOR NI) 20210212; UK FURTHER MAS ON IPSUM 20210212
1971601 CA 2021 00025 Denmark ⤷  Start Trial PRODUCT NAME: TUCATINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; NAT. REG. NO/DATE: EU/1/20/1526 20210212; FIRST REG. NO/DATE: CH 67798 20200507
1971601 C202130042 Spain ⤷  Start Trial PRODUCT NAME: TUCATINIB, OPCIONALMENTE EN FORMA DE UNA SAL O SOLVATO ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Zongertinib Market Dynamics and Financial Trajectory

Last updated: September 8, 2026

Zongertinib is Boehringer Ingelheim’s investigational, oral, irreversible HER2 tyrosine kinase inhibitor for non-small-cell lung cancer with activating HER2 mutations. Its commercial value depends on three factors: confirmation of response durability and intracranial activity, differentiation from trastuzumab deruxtecan, and successful expansion from a biomarker-defined salvage population into earlier-line treatment.

Zongertinib has no reported commercial revenue, no established product price, and no standalone valuation. Its financial trajectory is therefore development-stage rather than sales-driven. The asset has meaningful upside because HER2-mutant NSCLC is a defined precision-oncology segment with limited targeted competition, but the initial addressable population is small relative to broad EGFR-, ALK-, or KRAS-directed markets.

What is zongertinib and which cancer market does it target?

Zongertinib, also known as BI 1810631, is being developed for patients with activating HER2 mutations in unresectable or metastatic NSCLC. HER2 mutations are distinct from HER2 amplification or protein overexpression. The target population is concentrated within lung adenocarcinoma and is identified through molecular testing.

Attribute Zongertinib
Developer Boehringer Ingelheim
Drug class Irreversible HER2 tyrosine kinase inhibitor
Development code BI 1810631
Primary indication HER2-mutant unresectable or metastatic NSCLC
Administration Oral
Development status Investigational in the cited public record
Commercial sales None publicly reported
Main comparator Trastuzumab deruxtecan
Key clinical program Beamion LUNG
Regulatory designation FDA Breakthrough Therapy designation reported by Boehringer Ingelheim
Orange Book listing None before approval
Biosimilar exposure Not applicable to a small-molecule TKI

The commercial thesis is based on selective inhibition of mutant HER2 while attempting to limit inhibition of wild-type HER2. That design could support a more manageable safety profile than less selective pan-HER inhibitors, particularly in gastrointestinal toxicity. Clinical confirmation is required before that differentiation can support pricing or treatment-line expansion.

How large is the HER2-mutant NSCLC market?

The initial market is a niche segment of advanced NSCLC, not the entire lung-cancer market. HER2 mutations occur in approximately 1% to 4% of NSCLC cases, with variation by testing method, population, and disease subtype.[1]

A simplified U.S. market framework is:

Market factor Commercial implication
New U.S. lung and bronchus cancer cases Creates a large overall screening pool
NSCLC share Expands the relevant population
HER2-mutant prevalence Narrows the addressable segment
Advanced or metastatic disease Defines the initial treatment pool
Prior-treatment requirement Further restricts eligible patients
Molecular testing rates Determines diagnosis and treatment access
Duration of therapy Drives recurring revenue per patient

The initial U.S. patient pool for a HER2-mutant NSCLC therapy is likely measured in several thousand treated patients annually rather than tens of thousands. Global opportunity is larger, especially in Europe, Japan, China, and other markets with high lung-cancer incidence, but reimbursement and testing standards vary substantially.

Market expansion could come from three sources:

  1. Use after first-line therapy in patients with activating HER2 mutations.
  2. Earlier-line use before chemotherapy or immunotherapy exposure.
  3. Treatment of central nervous system disease if intracranial activity is confirmed.

How does zongertinib compare with Enhertu?

Trastuzumab deruxtecan, marketed as Enhertu by AstraZeneca and Daiichi Sankyo, is the most important commercial comparator. The FDA approved Enhertu for unresectable or metastatic NSCLC with activating HER2 mutations after prior systemic therapy in 2022.[2]

Factor Zongertinib Trastuzumab deruxtecan
Modality Oral small molecule Intravenous antibody-drug conjugate
Target HER2 kinase domain HER2-directed antibody with topoisomerase I payload
Treatment setting Investigational Approved in a post-treatment HER2-mutant NSCLC setting
Dosing convenience Potentially oral, outpatient-based Infusion-based
Key differentiation opportunity Mutation selectivity, oral delivery, CNS activity Established regulatory position and clinical validation
Major safety concern TKI-related gastrointestinal, hepatic, and dermatologic effects Interstitial lung disease, neutropenia, nausea
Revenue model Chronic oral therapy Per-infusion oncology therapy
Biosimilar risk None for the small molecule itself Potential long-term biologic competition

Zongertinib must show a clinically credible benefit over Enhertu, not merely activity in the same biomarker. The strongest differentiation would be a combination of durable systemic response, meaningful brain-metastasis control, lower treatment discontinuation, and easier administration.

Enhertu has first-mover advantages, including an established label, oncologist familiarity, reimbursement precedent, and a validated companion diagnostic pathway. Zongertinib’s oral format may improve convenience, but oral delivery does not automatically produce a lower total treatment cost.

What is the regulatory status of zongertinib?

Zongertinib was an investigational product in the cited public development record. Boehringer Ingelheim reported FDA Breakthrough Therapy designation for zongertinib in previously treated patients with unresectable or metastatic NSCLC harboring activating HER2 mutations.[3]

The key regulatory milestones are:

Milestone Status
First-in-human development Initiated
Phase 1 clinical evaluation Conducted in advanced solid tumors and HER2-mutant NSCLC
Phase 1b/2 Beamion development Ongoing in the cited record
FDA Breakthrough Therapy designation Reported by Boehringer Ingelheim
FDA approval Not established in the cited record
NDA approval date Not publicly established in the cited record
Orange Book listing None before approval
Pediatric exclusivity None
New chemical entity exclusivity Not available before approval

Breakthrough Therapy designation can accelerate FDA interaction and development planning. It does not guarantee approval, a specific review pathway, or commercial success.

What patents protect zongertinib?

Zongertinib’s protection is expected to rely primarily on composition-of-matter patents, pharmaceutical-composition claims, treatment methods, and potentially crystalline-form or manufacturing claims. Publicly disclosed commercial patent details are not sufficient to establish a definitive patent-expiration schedule or a complete international patent family.

The expected protection structure is:

Patent category Strategic purpose
Compound claims Core protection for zongertinib and related chemical species
Salt and polymorph claims Protection against formulation and solid-state substitutes
Pharmaceutical composition claims Covers dosage forms and excipient combinations
Method-of-use claims Covers treatment of HER2-mutant NSCLC
Biomarker claims Links treatment to activating HER2 mutations
Manufacturing claims Raises process-replication barriers
Formulation claims May protect oral dosage stability and release characteristics

Because zongertinib is not established as an FDA-approved product in the cited record, there is no Orange Book patent listing or regulatory exclusivity period to analyze. Any future U.S. launch would depend on the scope and enforceability of the issued composition patent, regulatory exclusivity, and the filing dates of applicable patent families.

When could zongertinib lose exclusivity?

A definitive loss-of-exclusivity date cannot be calculated from the cited public record. The relevant timeline would depend on:

  • The earliest effective U.S. nonprovisional patent filing date.
  • Patent-term adjustment.
  • Patent-term extension under 35 U.S.C. §156.
  • Any five-year new chemical entity exclusivity.
  • Pediatric exclusivity.
  • The scope of issued claims.
  • Paragraph IV challenges and settlement terms.

For a conventional small molecule, the core composition patent often determines the commercial exclusivity horizon. Method-of-use and formulation patents can delay or complicate generic entry, but they rarely provide the same protection as a valid, enforceable compound patent.

Are paragraph IV challenges or patent litigation affecting zongertinib?

No publicly established U.S. Paragraph IV litigation or ANDA challenge is identified in the cited development record. That result is expected for an investigational product without an Orange Book listing.

Litigation risk will increase after approval if the product achieves material sales. The most likely challenge points would be:

  1. A generic manufacturer’s assertion that the compound patent is invalid or not infringed.
  2. A skinny-label launch directed to uses outside patented indications.
  3. Challenges to formulation, salt, or polymorph patents.
  4. Disputes over the scope of HER2-mutant treatment claims.
  5. Patent-term calculations and regulatory exclusivity.

Settlement economics would depend on the remaining patent term, the size of the treated population, the challenger’s ability to launch, and the cost of litigation. No settlement agreement is publicly established in the cited record.

What is the financial trajectory for zongertinib?

Zongertinib has a pre-commercial financial profile. Boehringer Ingelheim does not report asset-level development spending, projected sales, or standalone operating profit for the program.

Financial phase Expected profile
Discovery and preclinical work R&D expense with no revenue
Early clinical development Rising clinical-trial and manufacturing costs
Pivotal development Highest regulatory, trial, and commercial-readiness spending
Approval and launch First product revenue; major sales-force and market-access costs
Early commercialization Rapid revenue growth if uptake is strong
Mature market Margin expansion, offset by rebates and competitive pricing
Post-exclusivity Price erosion and generic-entry risk

The major near-term financial burden is clinical development. Costs include global trial operations, biomarker testing, central laboratory services, regulatory submissions, drug supply, pharmacovigilance, and launch preparation.

A scenario framework illustrates the potential range:

Scenario Clinical outcome Commercial effect
Downside Response durability or safety is inadequate Program termination or restricted niche use
Base case Approval in previously treated HER2-mutant NSCLC Specialty oncology product with moderate peak sales
Upside Strong systemic and CNS data with earlier-line expansion Higher treatment duration, broader adoption, and multibillion-dollar potential across indications

Peak sales depend less on the raw incidence of HER2 mutations than on treatment duration, line of therapy, price, geographic reimbursement, and use in patients with brain metastases. A product used only after Enhertu or chemotherapy would have a smaller revenue ceiling than a first-line regimen.

What licensing deals or partnerships involve zongertinib?

Zongertinib is associated with Boehringer Ingelheim’s internal oncology pipeline. No major out-licensing transaction, co-development agreement, or acquisition assigning commercial rights to another company is established in the cited record.

That ownership structure gives Boehringer control over development sequencing, pricing strategy, manufacturing, and commercialization. It also means the program does not have a disclosed partner providing validation through a large upfront payment or milestone structure.

What manufacturing and intellectual-property barriers exist?

Zongertinib’s manufacturing barriers are moderate for a small-molecule oral drug. It does not require biologic cell culture, antibody-drug conjugate payload conjugation, or cold-chain distribution. The principal barriers are:

  • Reproducible synthesis of the active pharmaceutical ingredient.
  • Control of impurities and process-related variants.
  • Solid-state and polymorph control.
  • Scale-up validation.
  • Tablet or capsule stability.
  • Compliance with FDA and international current good manufacturing practice requirements.
  • Protection of proprietary intermediates and process conditions.

These barriers can slow generic entry but do not usually prevent competition after core composition patents expire. The strongest economic barrier should remain the composition-of-matter patent and the clinical evidence supporting physician adoption.

What generic launch risks exist?

Generic launch risk is currently pre-approval rather than immediate. After approval, risk will develop in stages:

Stage Risk
Pre-approval Patent scope and regulatory failure
Early launch Competitor clinical data and reimbursement restrictions
Mid-life cycle Paragraph IV challenges and alternative HER2 therapies
Late life cycle Generic TKI entry after core patent expiry
Post-expiry Rapid price erosion and payer substitution

A generic may attempt a narrow label if zongertinib receives multiple indications with different patent coverage. Method-of-use patents can be bypassed through a label excluding the patented indication, although actual prescribing behavior can create litigation disputes.

How strong is the commercial position of zongertinib?

Zongertinib’s commercial position is promising but unproven.

Its strengths are:

  • A genetically defined patient population.
  • Limited approved targeted options.
  • Oral administration.
  • Potential differentiation in CNS disease.
  • A focused development strategy.
  • Breakthrough Therapy designation.

Its constraints are:

  • Small initial addressable population.
  • Direct competition from Enhertu.
  • Dependence on HER2 testing rates.
  • Need to establish meaningful differentiation.
  • Possible TKI class toxicities.
  • No current product revenue.
  • No established Orange Book or exclusivity record.

The highest-value commercial outcome is an approved oral therapy with durable systemic and intracranial activity used before or alongside current post-treatment options. A narrower approval would support a specialty product but limit peak revenue.

Key Takeaways

  • Zongertinib is an investigational oral irreversible HER2 TKI developed by Boehringer Ingelheim for HER2-mutant NSCLC.
  • It has no publicly reported commercial revenue or standalone asset valuation.
  • The initial market is a small but commercially attractive precision-oncology segment.
  • Enhertu is the principal approved comparator and establishes the regulatory and clinical benchmark.
  • Zongertinib’s strongest potential differentiators are oral dosing, mutation selectivity, tolerability, and CNS activity.
  • No Orange Book listing, Paragraph IV litigation, or settlement agreement is established before approval.
  • Financial upside depends on expansion into earlier treatment lines and confirmation of durable clinical benefit.
  • Core compound patents are likely to determine the long-term exclusivity profile, but a definitive expiration date is not established in the cited record.

FAQs

Is zongertinib approved by the FDA?

Zongertinib was an investigational therapy in the cited public record. Boehringer Ingelheim reported FDA Breakthrough Therapy designation, which is not an approval.

What company owns zongertinib?

Boehringer Ingelheim is the disclosed developer and owner of the zongertinib program.

Is zongertinib a competitor to trastuzumab deruxtecan?

Yes. Both target patients with activating HER2 mutations in advanced NSCLC, although zongertinib is an oral small molecule and trastuzumab deruxtecan is an intravenous antibody-drug conjugate.

Does zongertinib have biosimilar competition?

No. Zongertinib is a small molecule, so its direct post-exclusivity threat would come from generic versions rather than biosimilars.

What would determine zongertinib’s peak sales?

The main variables are approval timing, treatment line, response durability, CNS efficacy, treatment duration, price, reimbursement, HER2 testing rates, and competitive positioning against Enhertu.

References

  1. Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O’Connell, C., Taylor, M. D., & others. (2015). Targeting HER2 aberrations as actionable drivers in lung cancers: Phase II trial of the irreversible pan-HER tyrosine kinase inhibitor neratinib in patients with HER2 mutation or amplification. Journal of Clinical Oncology, 33(24), 2715-2721.

  2. U.S. Food and Drug Administration. (2022). FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer. FDA.

  3. Boehringer Ingelheim. (2024). Boehringer Ingelheim announces FDA Breakthrough Therapy designation for zongertinib in HER2-mutant non-small cell lung cancer. Boehringer Ingelheim.

  4. ClinicalTrials.gov. (n.d.). Study of BI 1810631 in patients with advanced solid tumors and HER2 mutations. U.S. National Library of Medicine.

  5. Boehringer Ingelheim. (2023). Annual report 2023. Boehringer Ingelheim.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.